Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Eisenstadt – page 70

861 clinical trials in Eisenstadt, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Eisenstadt at a glance
861
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

861 trials in Eisenstadt

Open in trial search

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen - Cilag International

Type 2 diabetes mellitus+3

Not recruiting

Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Eli Lilly & Co.

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:BeOne Medicines AG

Study on Efinopegdutide and Semaglutide for Adults with Non-Alcoholic Steatohepatitis (NASH) Before Cirrhosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efinopegdutide
  • Sponsor:Merck Sharp & Dohme LLC

Study of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Macular oedema+1

Not recruiting

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-501A
  • Sponsor:Allogene Therapeutics Inc.

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol Myers Squibb International Corporation

Status epilepticus

Not recruiting

Study on Ganaxolone for Patients with Refractory Status Epilepticus

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ganaxolone
  • Sponsor:Marinus Pharmaceuticals Inc.

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Eisenstadt

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical research focusing on heart failure and pulmonary hypertension, specifically addressing conditions related to left heart disease. These trials aim to evaluate new therapeutic approaches for patients with complex cardiovascular conditions.

  • Heart Failure Management
  • Pulmonary Vascular Disease
  • Left Heart Disease Complications

The research examines treatment effectiveness in patients with WHO Group 2 pulmonary hypertension, exploring potential improvements in pulmonary vascular resistance over a 24-week period.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.